The Greater Cannabis Company, Inc. (GCAN) 10-K 26 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	Greater Cannabis Company, Inc.
Entity Central Index Key	0001695473
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		478,638,436
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 112,953	$ 24,662
Advance to supplier		28,000
Note receivable	36,750
Prepaid officer compensation	10,000
Total current assets	159,703	52,662
OTHER ASSETS
Right of first refusal agreement (less accumulated amortization of $ 4,583 and $ 0, respectively)	20,417
Total assets	180,120	52,662
CURRENT LIABILITIES
Accounts payable	6,743	17,517
Accrued interest	849	20,619
Accrued officer compensation	152,000	98,000
Accrued royalties		50,000
Advance from customer		27,977
Loans payable to related parties	260,000	260,000
Notes payable to third parties (less debt discounts of $0 and $505,937, respectively)	22,875	399,318
Derivative liability	17,441	725,865
Total current liabilities and total liabilities	459,908	1,599,296
STOCKHOLDERS' (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value:
Common stock; 500,000,000 shares authorized, $.001 par value, as of December 31, 2020 and 2019, there are 464,843,318 and 39,301,323 shares outstanding, respectively	464,843	39,301
Additional paid-in capital	2,576,365	783,891
Accumulated deficit	(3,330,408)	(2,379,238)
Total stockholders' (deficiency)	(279,788)	(1,546,634)
Total liabilities and stockholders' (deficiency)	180,120	52,662
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value:	9,412	9,412
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' (DEFICIENCY)
Preferred stock; 19,000,000 shares authorized, $.001 par value:

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Right of first refusal agreement	$ 4,583	$ 0
Debt discount	$ 0	$ 505,937
Preferred stock, shares authorized	19,000,000	19,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares outstanding	464,843,318	39,301,323
Series A Convertible Preferred Stock [Member]
Preferred stock, shares issued	9,411,998	9,411,998
Preferred stock, shares outstanding	9,411,998	9,411,998
Series B Convertible Preferred Stock [Member]
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 48,044	$ 7,120
Cost of product sales	48,090	3,125
Gross profit (loss)	(46)	3,995
Operating Expenses:
Minimum royalties expense		50,000
Officers compensation	204,000	204,000
Amortization of right of first refusal agreement	4,583
Amortization of Pharmedica Exclusive License Agreement cost		20,000
Impairment charge-Pharmedica Exclusive License Agreement cost		69,749
Other operating expenses (including stock-based professional fees of $0 and $88,130, respectively)	85,828	185,569
Total operating expenses	294,411	529,318
Income (loss) from operations	(294,457)	(525,323)
Other income (expenses):
Income (expense) from derivative liability	1,218,090	(303,981)
Loss on conversions of notes payable and accrued interest to common stock	(1,291,604)	(320,025)
Gain from Surrender Agreement with Emet Capital Partners, LLC	472,170
Interest expense	(89,766)	(35,776)
Forgiveness of royalty payable	50,000
Amortization of debt discounts	(1,015,603)	(463,490)
Total other income (expenses)	(656,713)	(1,123,272)
Income (loss) before provision for income taxes	(951,170)	(1,648,595)
Provision for income taxes
Net income (loss)	$ (951,170)	$ (1,648,595)
Basic and diluted income (loss) per common share	$ (.01)	$ (.05)
Weighted average common shares outstanding-basic and diluted	145,332,999	34,980,133
Product Sales [Member]
Revenue:
Total revenue	$ 48,044	$ 4,500
Consulting Fees [Member]
Revenue:
Total revenue		$ 2,620

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Stock-based consulting fees	$ 0	$ 88,130

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Series A Preferred Stock [Member]
Beginning Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412
Beginning Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock
Conversions of note payable and accrued interest into shares of common stock, shares
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares
Issuance of common shares for professional services rendered
Issuance of common shares for professional services rendered, shares
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares
Net loss
Ending Balance	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412	$ 9,412
Ending Balance, shares	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998	9,411,998
Series B Preferred Stock [Member]
Beginning Balance					$ 9,000	$ 9,000	$ 9,000
Beginning Balance, shares					9,000,000	9,000,000	9,000,000
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock
Conversions of note payable and accrued interest into shares of common stock, shares
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019								$ 9,000
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019, shares								9,000,000
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares
Issuance of common shares for professional services rendered
Issuance of common shares for professional services rendered, shares
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock					$ (9,000)
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock					(9,000,000)
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares
Net loss
Ending Balance						$ 9,000	$ 9,000	$ 9,000
Ending Balance, shares						9,000,000	9,000,000	9,000,000
Common Stock [Member]
Beginning Balance	$ 203,627	$ 88,350	$ 60,786	$ 39,301	$ 35,447	$ 35,272	$ 33,346	$ 31,881	$ 39,301	$ 31,881
Beginning Balance, shares	203,627,370	88,349,536	60,786,011	39,301,323	35,447,483	35,272,483	33,345,883	31,880,969	39,301,323	31,880,969
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock	$ 261,216	$ 115,277	$ 27,564	$ 21,485				$ 770
Conversions of note payable and accrued interest into shares of common stock, shares	261,215,948	115,277,834	27,563,525	21,484,688				769,785
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019								$ 695
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019, shares								695,129
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019							$ 1,384
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019, shares							1,384,600
Issuance of common shares for professional services rendered						$ 175	$ 542
Issuance of common shares for professional services rendered, shares						175,000	542,000
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019					$ 1,749
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019, shares					1,748,363
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019					$ 1,468
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019, shares					1,468,204
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019					$ 637
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019, shares					637,273
Net loss
Ending Balance	$ 464,843	$ 203,627	$ 88,350	$ 60,786	$ 39,301	$ 35,447	$ 35,272	$ 33,346	$ 464,843	$ 39,301
Ending Balance, shares	464,843,318	203,627,370	88,349,536	60,786,011	39,301,323	35,447,483	35,272,483	33,345,883	464,843,318	39,301,323
Additional Paid in Capital [Member]
Beginning Balance	$ 2,033,257	$ 1,351,467	$ 1,168,499	$ 783,891	$ 589,625	$ 577,550	$ 323,598	$ 233,991	$ 783,891	$ 233,991
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019
Conversions of note payable and accrued interest into shares of common stock	543,108	681,790	182,968	384,608				99,302
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019								(695)
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019								(9,000)
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019							178,614
Issuance of common shares for professional services rendered						12,075	75,338
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock					9,000
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019					103,152
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019					57,260
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019					24,854
Net loss
Ending Balance	2,576,365	2,033,257	1,351,467	1,168,499	783,891	589,625	577,550	323,598	2,576,365	783,891
Accumulated Deficit [Member]
Beginning Balance	(2,947,618)	(2,488,358)	(3,590,807)	(2,379,238)	(1,283,201)	(1,156,771)	(868,992)	(839,070)	(2,379,238)	(839,070)
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019								108,427
Conversions of note payable and accrued interest into shares of common stock
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019
Issuance of common shares for professional services rendered
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019
Net loss	(382,790)	(459,260)	1,102,449	(1,211,569)	(1,096,037)	(126,430)	(287,779)	(138,349)
Ending Balance	(3,330,408)	(2,947,618)	(2,488,358)	(3,590,807)	(2,379,238)	(1,283,201)	(1,156,771)	(868,992)	(3,330,408)	(2,379,238)
Beginning Balance	(701,322)	(1,039,129)	(2,352,110)	(1,546,634)	(639,717)	(525,537)	(493,636)	(563,786)	(1,546,634)	(563,786)
Cumulative effect adjustment to reduce derivative liability of warrants with "down round" features effective January 1, 2019								108,427
Conversions of note payable and accrued interest into shares of common stock	804,324	797,067	210,532	406,093				100,072
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019
Conversion of note payables ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (Fair Value of $100,072) on April 16, 2019							179,998
Issuance of common shares for professional services rendered						12,250	75,880
Exchange Agreement dated October 18, 2019, provided for the reversal of the February 14, 2019 agreement to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019					104,901
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019					58,728
Conversion of note payables ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $58,728) on December 24, 2019					25,491
Net loss	(382,790)	(459,260)	1,102,449	(1,211,569)	(1,096,037)	(126,430)	(287,779)	(138,349)	(951,170)	(1,648,595)
Ending Balance	$ (279,788)	$ (701,322)	$ (1,039,129)	$ (2,352,110)	$ (1,546,634)	$ (639,717)	$ (525,537)	$ (493,636)	$ (279,788)	$ (1,546,634)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Parenthetical) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Feb. 14, 2019	Jan. 04, 2019	Mar. 10, 2017	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019
Conversion of note payable	$ 10,000	$ 29,000	$ 53,705	$ 40,500		$ 670		$ 325,212	$ 311,050	$ 67,082	$ 165,350
Accrued interest	$ 515	$ 4,035	$ 2,680	$ 7,961		$ 100		$ 16,849	$ 18,462	$ 10,613	$ 11,793
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600		769,785		261,215,948	115,277,834	27,563,525	21,484,688
Debt conversion of shares, value	$ 25,491	$ 58,728	$ 104,901	$ 179,998		$ 100,072		$ 804,324	$ 797,067	$ 210,532	$ 406,093
Exercise of warrants						1,400
Issuance of common stock in cashless exercise transaction, shares						695,129	26,905,969
Exchange of warrants					438,600
Common Stock [Member]
Issuance of common shares for professional services												175,000	542,000
Class B Convertible Preferred Stock [Member]
Conversion of convertible preferred stock					9,000,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
OPERATING ACTIVITIES
Net income (loss)	$ (951,170)	$ (1,648,595)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:
Loss on conversions of notes payable and accrued interest to common stock	1,291,604	320,025
Gain from Surrender Agreement with Emet Capital Partners, LLC	(472,170)
Issuance of stock-based professional fees		88,130
Forgiveness of royalty payable	(50,000)
(Income) expense from derivative liability	(1,218,090)	303,981
Amortization of right of first refusal agreement	4,583
Amortization of Pharmedica Exclusive License Agreement cost		20,000
Impairment charge- Pharmedica Exclusive License Agreement cost		69,749
Interest expense for default added to note payable balance
Amortization of debt discounts	1,015,603	463,490
Changes in operating assets and liabilities:
Advance to supplier	28,000	(28,000)
Prepaid officer compensation	(10,000)
Accounts payable	(10,774)	(383)
Accrued interest	56,764	35,397
Accrued officer compensation	54,000	13,000
Accrued royalties		50,000
Advance from customer	(27,977)	27,977
Net cash used in operating activities	(289,627)	(285,229)
INVESTING ACTIVITIES
Note receivable	(36,750)
Purchase of Right of First Refusal Agreement	(25,000)
Net cash used in investing activities	(61,750)
FINANCING ACTIVITIES
Amount paid in connection with Surrender Agreement with Emet Capital Partners, LLC	(70,000)
Proceeds from notes payable to third parties	509,668	250,000
Net cash provided by financing activities	439,668	250,000
NET INCREASE (DECREASE) IN CASH	88,291	(35,229)
CASH BALANCE, BEGINNING OF PERIOD	24,662	59,891
CASH BALANCE, END OF PERIOD	112,953	24,662
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income tax paid
Non-cash Investing and Financing Activities:
Conversion of note payable ($670) and accrued interest ($100) into 769,785 shares of common stock (Fair Value of $100,072) on January 4, 201911		100,072
Exercise of 1400 warrants into 695,129 shares of common stock in a cashless exercise transaction on January 4, 2019		695
Exchange of 438,600 warrants into 9,000,000 shares of Class B Convertible Preferred Stock on February 14, 2019. Exchange Agreement reversed on October 18, 2019
Initial derivative liability charged to debt discount	509,667	250,000
Conversion of note payable ($40,500) and accrued interest ($7,961) into 1,384,600 shares of common stock (fair value of $179,998) on April 16, 2019		179,998
Conversion of note payables ($53,705) and accrued interest ($2,680) into 1,748,363 shares of common stock (Fair Value of $104,901) on November 11, 2019		104,901
Conversion of note payable ($29,000) and accrued interest ($4,035) into 1,468,204 shares of common stock (Fair Value of $58,728) on December 20, 2019		58,728
Conversion of note payable ($10,000) and accrued interest ($515) into 637,273 shares of common stock (Fair Value of $25,491) on December 24, 2019		25,491
Conversions of notes payable ($165,350) and accrued interest ($11,793) into 21,484,688 shares of common stock (Fair Value of $ 406,093) for the three months ended March 31, 2020	406,093
Conversions of notes payable ($67,082) and accrued interest ($10,613) into 27,563,525 shares of common stock (Fair Value of $ 210,532) for the three months ended June 30, 2020	210,532
Conversions of notes payable ($311,050) and accrued interest ($18,462) into 115,277,834 shares of common stock (Fair Value of $797,067) for the three months ended September 30, 2020	797,067
Conversions of notes payable ($325,212) and accrued interest ($16,849) into 261,215,948 shares of common stock (Fair Value of $804,324) for the three months ended December 31, 2020	$ 804,324

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($)	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Apr. 16, 2019	Feb. 14, 2019	Jan. 04, 2019	Mar. 10, 2017	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Conversion of note payable	$ 10,000	$ 29,000	$ 53,705	$ 40,500		$ 670		$ 325,212	$ 311,050	$ 67,082	$ 165,350
Accrued interest	$ 515	$ 4,035	$ 2,680	$ 7,961		$ 100		$ 16,849	$ 18,462	$ 10,613	$ 11,793
Debt conversion converted shares issued	637,273	1,468,204	1,748,363	1,384,600		769,785		261,215,948	115,277,834	27,563,525	21,484,688
Debt conversion of shares, value	$ 25,491	$ 58,728	$ 104,901	$ 179,998		$ 100,072		$ 804,324	$ 797,067	$ 210,532	$ 406,093
Exercise of warrants						1,400
Issuance of common stock in cashless exercise transaction, shares						695,129	26,905,969
Exchange of warrants					438,600
Class B Convertible Preferred Stock [Member]
Conversion of convertible preferred stock					9,000,000

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Nature of Operations and Summary of Significant Accounting Policies	NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize the Technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx, Inc. Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents. Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods. Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values. Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party. Revenue Recognition Revenue from product sales is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred. Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs. Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note H), shares relating to convertible notes payable to third parties (Please see NOTE F - NOTES PAYABLE TO THIRD PARTIES see NOTE H - CAPITAL STOCK AND WARRANTS Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presented. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative effect adjustment reduction of accumulated deficit.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE B - GOING CONCERN Under ASC 205-40, we have the responsibility to evaluate whether conditions and/or events raise substantial doubt about our ability to meet our future obligations as they become due within one year after the date the financial statements are issued. As required by this standard, our evaluation shall initially not take into consideration the potential mitigating effects of our plans that have not been fully implemented as of the date the financial statements are issued. In performing the first step of this assessment, we concluded that the following conditions raise substantial doubt about our ability to meet our financial obligations as they become due. As of December 31, 2020, the Company had cash of $112,953, total current liabilities of $459,908, and negative working capital of $300,205. For the year ended December 31, 2020, we incurred a net loss of $951,170 and used $289,627 cash from operating activities. We expect to continue to incur negative cash flows until such time as our business generates sufficient cash inflows to finance our operations and debt service requirements. In performing the second step of this assessment, we are required to evaluate whether our plans to mitigate the conditions above alleviate the substantial doubt about our ability to meet our obligations as they become due within one year after the date that the financial statements are issued. Our future plans include securing additional funding sources. There is no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available through external sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material effect on the business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing shareholders. We have therefore concluded there is substantial doubt about our ability to continue as a going concern through March 2022. The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of the uncertainty related to our ability to continue as a going concern.

Note Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Note Receivable	NOTE C- NOTE RECEIVABLE On June 10, 2020, in anticipation of developing a CBD business with Kol Tuv Ventures, LLC (the “Borrower”) (see Note D), the Company agreed to lend the Borrower USD $50,000 to be repaid either (a) out of available cash as soon as practicable, including from sales of Bob Ross cosmetic products, or (b) on the date that is 18 months from the date thereof, whichever is earlier (the “Maturity Date”). The Loan shall not bear interest except to the extent that any part of the Loan remains outstanding as at the Maturity Date, in which case the following sentence applies. From the date after the Maturity Date and onward, the outstanding principal amount of the Loan shall bear interest at a rate of 2% per annum. Any payment of cash to be made by Borrower to Lender shall be applied first to outstanding principal and second to any accrued, but unpaid, interest. As of December 31, 2020, the balance of the note was $ 36,750.

Right of First Refusal Agreemen

Right of First Refusal Agreement	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Right of First Refusal Agreement	NOTE D – RIGHT OF FIRST REFUSAL AGREEMENT On January 30, 2020, the Company executed a Right of First Refusal Agreement with an entity engaged in the business of cosmetics, health, and well-being. The Agreement provided for the Company to pay Kol Tuv Ventures, LLC (“KTV”), $25,000 on January 30, 2020 (which was paid January 30,2020) and to make other investments in opportunities to be pursued by KTV and/or payments to KTV to enable KTV to pursue and secure Cannabidiol (“CBD”) opportunities. The Agreement provides the Company an exclusive right of first refusal to participate in all CBD opportunities to be pursued by KTV for a term of five years. The $25,000 cost for this Agreement is being amortized over the five year term of the Agreement.

Loans Payable to Related Partie

Loans Payable to Related Parties	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Loans Payable to Related Parties	NOTE E - LOANS PAYABLE TO RELATED PARTIES Loans payable to related parties consist of: December 31, 2020 December 31, 2019 Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000 Pursuant to loan and contribution agreements dated July 31, 2018, the above loans are non-interest bearing and are to be repaid after the Company raises from investors no less than $1,500,000 or generates sufficient revenue to make repayments (each, a “Replacement Event”). If the First Replacement Event does not occur within 18 months from July 31, 2018, the loans are to be repaid immediately. In the event there is insufficient capital to repay the loans, the lenders have the option to convert all or part of the loans into shares at the Company common stock at the average trading price of the 10 days prior to the date of the conversion request.

Notes Payable to Third Parties

Notes Payable to Third Parties	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable to Third Parties	NOTE F - NOTES PAYABLE TO THIRD PARTIES Notes payable to third parties consist of: December 31, 2020 December 31, 2019 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 2,420 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 1,100 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Convertible Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $33,396, respectively (i) 22,500 250,082 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $294,234, respectively (ii) - 74,566 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $90,054, respectively (ii) - 22,823 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $79,248, respectively (ii) - 20,084 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $9,005, respectively (ii) - 2,281 Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (ii) - 25,587 Total $ 22,875 $ 399,318 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle was to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company’s common stock for the preceding 15 trading days prior to the conversion date. Please see Note G-DERIVATIVE LIABILITY for further information. (ii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note H) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. On May 26, 2020, the Company entered into a Surrender Agreement with Emet Capital Partners, LLC (“Emet”) pursuant to which Emet agreed to surrender its interests in the following convertible notes such notes in exchange for a payment of $70,000: 1. Convertible Redeemable Note issued on 10/18/19 in the amount of $3,128.79 2. Convertible Redeemable Note issued on 10/18/19 in the amount of $15,439.93 3. Convertible Redeemable Note issued on 10/18/19 in the amount of $7,018.15 4. Convertible Note issued on 10/18/19 in the amount of $451,504.95 5. Convertible Note issued on 10/18/19 in the amount of $112,876.28 6. Convertible Note issued on 10/18/19 in the amount of $99,331.13 7. Convertible Note issued on 10/18/19 in the amount of $11,287.65 The $472,170 excess of the $ 542,170 remaining amount of debt satisfied over the $ 70,000 cash payment was recognized as a gain in the three months ended June 30, 2020.

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	NOTE G - DERIVATIVE LIABILITY The derivative liability consists of: December 31, 2020 December 31, 2019 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ 17,441 $ 182,625 Convertible Promissory Notes dated October 18, 2019 payable to Emet. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (ii): $451,505 note due October 18, 2021 - 328,953 $112,876 note due October 18, 2021 - 100,680 $ 99,331 note due October 18, 2021 - 88,599 $ 11,288 note due October 18, 2021 - 10,068 $ 25,587 note due October 18, 2021 - 14,940 Total derivative liability $ 17,441 $ 725,865 The Convertible Promissory Notes (the “Notes”) contain a variable conversion feature based on the future trading price of the Company’s common stock. Therefore, the number of shares of common stock issuable upon conversion of the Notes is indeterminate. The fair value of the derivative liability is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculation of the derivative liability of the Notes at December 31, 2020 were (1) stock price of $.003 per share, (2) conversion price of $.00169 per share, (3) term of 0 days, (4) expected volatility of 142.94%, and (5) risk free interest rate of 0%. Assumptions used for the calculations of the derivative liability of the Notes at December 31, 2019 were (1) stock price of $ .0330 per share, (2) conversion prices ranging from $ .01885 to $ .02175 per share, (3) terms ranging from 43 days to 293 days, (4) expected volatility of 142,94%, and (5) risk free interest rates ranging from 1.50% to 1.60%. (i)As discussed in Note A above, warrants with “down round” features (and do not contain variable conversion features) are not subject to derivative liability treatment effective January 1, 2019.

Capital Stock and Warrants

Capital Stock and Warrants	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Capital Stock and Warrants	NOTE H - CAPITAL STOCK AND WARRANTS Preferred Stock On July 31, 2018, The Greater Cannabis Company, Inc. (the “Company”) acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to 50 votes on all matters as a class with the holders of common stock. On February 14, 2019, the Company issued 9,000,000 shares of Series B Convertible Preferred Stock to Emet Capital Partners, LLC (“Emet”) in exchange for the surrender of all outstanding warrants held by Emet. Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $0.075 per share. On October 18, 2019, this exchange agreement was reversed. (See Note F) Common Stock Effective March 10, 2017, in connection with a partial spin-off of the Company from Sylios Corp, the Company issued a total of 26,905,969 shares of its common stock. 5,378,476 shares were issued to Sylios Corp (representing 19.99% of the issued and outstanding shares of Company common stock after the spin-off) and 21,527,493 shares were issued to the stockholders of record of Sylios Corp on February 3, 2017 on the basis of one share of Company common stock for each 500 shares of Sylios Corp common stock held (representing 80.01% of the issued and outstanding shares of Company common stock after the spin-off). On January 4, 2019, the Company issued 769,785 shares of its common stock pursuant to a conversion of $670 principal and $100 accrued interest of its convertible note dated May 25, 2018 by Emet Capital Partners, LLC (“Emet”). This conversion was based on a conversion price of $0.001 per share (rather than the Variable Conversion Price provided in the related note) submitted by Emet in its Conversion Notice. Emet asserted that the Company had committed a dilutive issuance, which triggered the “ratchet-down” provision of the related note which provides for a reduction of the conversion price. The $99,302 excess of the $100,072 fair value of the 769,785 shares over the $770 liability reduction was charged to Loss on Conversion of Debt in the three months ended March 31, 2019. On January 4, 2019, the Company issued 695,129 shares of its common stock pursuant to an exercise of the equivalent of 1,400 warrants (of the 440,000 warrants issued to Emet Capital Partners, LLC on May 25, 2017) in a cashless exercise transaction based on a ratchet-down exercise price of $0.001 per share. On April 16, 2019, the Company issued 1,384,600 shares of its common stock pursuant to conversions of $40,500 principal and $7,961 accrued interest of two convertible notes issued to by Emet Capital Partners, LLC (“Emet”). The $131,537 excess of the $179,998 fair value of the 1,384,600 shares over the $47,961 liability reduction was charged to Loss on Conversion of Debt in the three months ended June 30, 2019. On May 29, 2019, the Company issued a total of 542,000 shares of its common stock to two consulting firm entities for certain specified investor relations and advisory services. The $75,880 fair value of the 542,000 shares was charged to Other Operating Expenses in the three months ended June 30, 2019. On August 15, 2019, the Company issued 175,000 shares of its common stock to an entity consultant for accounting services rendered. The $12,250 fair value of the 175,000 shares was charged to Other Operating Expenses. On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bear interest at 6%, are due on February 12, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note G) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new note bear interest at 2%, are due on October 18, 2020 and are convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. On November 11, 2019, the Company issued 1,748,363 shares of its common stock pursuant to a conversion of $53,705 principal and $2,680 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 20, 2019, the Company issued 1,468,204 shares of its common stock pursuant to a conversion of $29,000 principal and $4,015 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. On December 24, 2019, the Company issued 637,273 shares of its common stock pursuant to a conversion of $10,000 principal and $515 accrued interest and fees of its convertible note dated October 18, 2019 by Emet. During the three months ended March 31, 2020, the Company issued a total of 21,484,688 shares of common stock pursuant to conversions of an aggregate of $165,350 in principal and $11,793 in interest under our outstanding convertible notes. The $228,949 excess of the $406,093 fair value of the 21,484,688 shares of common stock at the respective dates of issuance over the $177,143 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended June 30, 2020, the Company issued a total of 27,563,525 shares of common stock pursuant to conversions of an aggregate of $67,082 in principal and $10,613 in interest under our outstanding convertible notes. The $132,838 excess of the $210,532 fair value of the 27,563,525 shares of common stock at the respective dates of issuance over the $77,695 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended September 30, 2020, the Company issued a total of 115,277,834 shares of common stock pursuant to conversions of an aggregate of $311,050 in principal and $18,462 in interest under our outstanding convertible notes. The $467,554 excess of the $797,067 fair value of the 115,277,834 shares of common stock at the respective dates of issuance over the $329,512 liability reduction was charged to Loss on Conversions of Notes Payable. During the three months ended December 31, 2020, the Company issued a total of 261,215,948 shares of common stock pursuant to conversions of an aggregate of $325,212 in principal and $16,849 in interest under our outstanding convertible notes. The $462,263 excess of the $804,324 fair value of the 261,215,948 shares of common stock at the respective dates of issuance over the $342,061 liability reduction was charged to Loss on Conversions of Notes Payable. Emet Warrant Restructuring On February 14, 2019, the Company entered into an exchange agreement with Emet Capital Partners, LLC (“Emet”) pursuant to which the Company issued Emet 9,000,000 shares of its Series B Convertible Preferred Stock (the “Series B Preferred Shares”) in exchange for the surrender of all outstanding warrants held by Emet. Each Series B Preferred Share was convertible into one share of the Company’s common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company’s common stock was less than $0.075. In such case, Emet was to receive an additional number of shares of common stock equal to the number of shares being converted divided by the applicable market price. On October 18, 2019, this exchange agreement was reversed and the warrants were exchanged for four new convertible notes payable to Emet in the total amount of $ 675,000. See Note F above. At December 31, 2020 and 2019, the Company had no outstanding warrants.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE I - INCOME TAXES The Company and its United States subsidiaries expect to file consolidated Federal income tax returns. Green C Corporation, its Ontario Canada subsidiary, will file Canada and Ontario income tax returns. At December 31, 2020 the Company has available for federal income tax purposes a net operating loss carry forward that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is not more likely than not that the benefits will be realized. Due to significant changes in the Company’s ownership, the future use of its existing net operating losses will be limited. All tax years of the Company and its United States subsidiaries remain subject to examination by the Internal Revenue Service.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE J - COMMITMENTS AND CONTINGENCIES Pharmedica Exclusive License Agreement On June 21, 2018, Green C executed an Exclusive License Agreement with Pharmedica, Ltd. (“Pharmedica”), an Israeli company, to exploit certain Pharmedica intellectual property for the development and distribution of a certain Licensed Product involved in the transmucosal delivery of medicinal or recreational cannabis. The agreement provides for Green C payments to Pharmedica of a $100,000 license fee (which was paid by 2591028 Ontario Limited, an entity affiliated with Green C’s Chief Executive Officer, on June 26, 2018) and annual royalties at a rate of 5% of the Net Sales of the Licensed Product subject to a Minimum Annual Royalty of $50,000. The agreement also provides for certain milestones to be accomplished by Green C in order for Green C to retain the license. Green C and Pharmedica each may terminate the agreement upon the occurrence of a material breach by the other party of its obligations under the agreement and such other party’s failure to remedy such breach to the reasonable satisfaction of the other party within thirty (30) days after being requested in writing to do so. The Company generated only minimal revenues from this asset through December 31, 2019 and did not pay the Year 1 Minimum Annual Royalty of $50,000 due Pharmedica. Accordingly, we recorded an impairment charge of $69,749 at December 31, 2019 and reduced the $69,749 remaining carrying value of this intangible asset to $0. On September 2, 2020, Green C notified Pharmedica of Green C’s termination of the Exclusive License Agreement and Green C’s intention to wind up Green C. On September 17, 2020, Pharmedica notified Green C of Pharmedica’s acceptance of Green C’s proposal to terminate the license agreement and Pharmedica’s intention not to burden Green C further. Accordingly, we recorded “Forgiveness of Royalty Payable” other income of $50,000 in the three months ended September 30, 2020 and reduced the $50,000 “Accrued Royalties” liability balance to $0. Sub-License Agreement with Symtomax Unipessoal Lda On July 15, 2019, the Company executed a Sub-License Agreement with Symtomax Unipessoal Lda (“Symtomax”). The agreement provides for the Company’s grant to Symtomax of a non-exclusive right and sub-license to use certain Company technology and intellectual property to develop and commercialize products for sale in Europe, the Middle East, and Africa. The agreement provides for Symtomax payments of royalties to the Company (payable monthly) ranging from 10% to 17% of Symtomax sales of eluting patches developed from Company technology. On May 27, 2020, the Company executed an amended and restated sub-license agreement with Symtomax (the “Amended License Agreement”). The term of the Amended License Agreement ends the earlier of (i) August 31, 2021 and (ii) the date that Symtomax is no longer commercializing any of the products. The term is extended for an additional year on each anniversary of the agreement for any country where the royalty payment in respect of such country was equal to or greater than $1,000,000 for the previous year. To date, Symtomax has not made any sales requiring the payment of royalties to the Company. Service Agreements On July 31, 2018, the Company executed Services Agreements with its newly appointed Chief Executive Officer (the “CEO”) and its newly appointed Chief Legal Officer (the “CLO”), for terms of five years. The Agreements provide for a monthly base salary of $10,000 for the CEO and a monthly base salary of $7,000 for the CLO. For the years ended December 31, 2020 and 2019, the Company expensed a total of $204,000 and $204,000, respectively, as officers compensation pursuant to these agreements. Sales Concentration One customer accounted for 100% of sales in the year ended December 31, 2020.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE K – SUBSEQUENT EVENTS On January 6, 2021, On March 15, 2021, we We have also agreed to file a registration statement on Form S-1 to register the shares of common stock issuable upon the conversion of the FF Note by FF. Upon effectiveness of the registration statement, FF will lend us the lesser of (i) $272,500.00 of principal; or (ii) the amount that FF can purchase and include in the registration statement. FF Note The FF Note will mature on March 11, 2022. The FF Note may be pre-paid in whole or in part by paying FF the following premiums: PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I) Any amount of principal or interest on the FF Note, which is not paid when due shall bear interest at the rate of twenty-four (24%) per annum from the due date thereof until the same is paid (“Default Interest”). FF has the right beginning on the date which is one hundred eighty (180) days following the Issue Date to convert all or any part of the outstanding and unpaid principal amount of the FF Note into fully paid and non-assessable shares of our common stock at the conversion price (the “Conversion Price”). The Conversion Price shall be, equal to 7 0 A copy of the FF Note was attached as Exhibit 10.1 to our current report on Form 8-K dated March 16, 2021 and the above summary of the FF Note terms is subject to full terms of the FF Note. Registration Rights Agreement On March 11, 2021, we entered into a registration rights agreement pursuant to which we agreed to prepare and file with the SEC a registration statement or registration statements (as is necessary) covering the resale of all of the shares of common stock into which the FF Note is convertible and the shares to be received upon the exercise of the warrants. The registration statement also covers such indeterminate number of additional shares of securities as may become issuable upon stock splits, stock dividends or similar transactions. We agreed to use its best efforts to have the registration statement filed with the SEC within thirty (30) days following the closing date. A copy of the registration rights agreement is attached as Exhibit 10.2 to our current report on Form 8-K dated March 16, 2021 and the above summary of the registration rights agreement terms is subject to full terms of the registration rights agreement. FF Warrants On March 11, 2021, we also issued three warrants (Warrant A, Warrant B and Warrant C) to purchase shares of our common stock, as follows: Warrant A permits FF to purchase 25,000,000 shares of common stock at an exercise price of $0.025 per share. Warrant B permits FF to purchase 15,000,000 shares of common stock at an exercise price of $0.05 per share. Warrant C permits FF to purchase 10,000,000 shares of common stock at an exercise price of $0.075 per share. Each warrant has other customary terms found in like instruments, including, but not limited to, events of default. In any event of default, the exercise price for each warrant automatically becomes $0.005 per share. Copies of Warrant A, Warrant B and Warrant C are attached as Exhibits 10.4, 10.5 and 10.6 to our current report on Form 8-K dated March 16, 2021 and the above summary of the warrant terms are subject to full terms of the applicable warrants.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations The Greater Cannabis Company, Inc. (the “Company”) was formed in March 2014 as a limited liability company under the name, The Greater Cannabis Company, LLC. The Company was a wholly owned subsidiary of Sylios Corp (“Sylios”) until March 10, 2017. On July 31, 2018, the Company acquired 100% of the issued and outstanding shares of Class A common stock of Green C Corporation (“Green C”) in exchange for 9,411,998 newly issued shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”). Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock. Since after the Exchange was consummated, the former shareholders of Green C and their designees owned approximately 94% of the issued and outstanding voting shares of the Company, Green C is the acquirer for accounting purposes. Prior to the Exchange, the Company had no assets and nominal business operations. Accordingly, the Exchange has been treated for accounting purposes as a recapitalization by the accounting acquirer, Green C, and the accompanying consolidated financial statements of the Company reflect the assets, liabilities and operations of Green C from its inception on December 21, 2017 to July 31, 2018 and combined with the Company thereafter. Green C was incorporated on December 21, 2017 under the laws of the Province of Ontario Canada with its principal place of business in North York, Ontario. Green C was the owner of an exclusive, worldwide license for an eluting transmucosal patch platform (“ETP”) for non-invasive drug delivery in the cannabis field as further described in the exclusive license agreement dated June 21, 2018 with Pharmedica Ltd. (see Note J). The Company’s business plan is to (i) commercialize the Technology and (ii) concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of The Greater Cannabis Company, Inc., and its wholly owned subsidiaries Green C Corporation and Biocanrx, Inc.
Cash and Cash Equivalents	Cash and Cash Equivalents Investments having an original maturity of 90 days or less that are readily convertible into cash are considered to be cash equivalents. For the periods presented, the Company had no in cash equivalents.
Income Taxes	Income Taxes In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The asset and liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements. The resulting deferred tax assets or liabilities are adjusted to reflect changes in tax laws as they occur. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a “more-likely-than-not” threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of December 31, 2020, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no foreign federal or state tax examinations nor have we had any foreign federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Financial Instruments and Fair Value of Financial Instruments	Financial Instruments and Fair Value of Financial Instruments We follow ASC Topic 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. Except for derivative liabilities, we had no financial assets or liabilities carried and measured on a recurring or nonrecurring basis during the reporting periods.
Derivative Liabilities	Derivative Liabilities We evaluate convertible notes payable, stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Long-lived Assets	Long-lived Assets Long-lived assets such as property and equipment and intangible assets are periodically reviewed for impairment. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Equity Instruments Issued to Non-employees for Acquiring Goods or Services	Equity Instruments Issued to Non-Employees for Acquiring Goods or Services Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service may be fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments are fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to expense over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values.
Related Parties	Related Parties A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.
Revenue Recognition	Revenue Recognition Revenue from product sales is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists, (2) the price is fixed or determinable, (3) collectability is reasonably assured, and (4) delivery has occurred.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. For the periods presented, we had no advertising costs.
Loss Per Share	Loss per Share We compute net loss per share in accordance with FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock. Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options, warrants and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net loss per share are excluded from the calculation. For the periods presented, the Company excluded 470,599,900 shares relating to the Series A Convertible Preferred Stock (see Note H), shares relating to convertible notes payable to third parties (Please see NOTE F - NOTES PAYABLE TO THIRD PARTIES see NOTE H - CAPITAL STOCK AND WARRANTS
Recently Enacted Accounting Standards	Recently Enacted Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all prior revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under prior U.S. GAAP. As amended by the FASB in July 2015, the standard became effective for annual periods beginning after December 15, 2017, and interim periods therein. ASU 2014-09 has had no impact on our Financial statements for the periods presented. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-08 has had no impact on our Financial statements for the periods presented. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). ASU 2016-10 has had no impact on our financial statements for the periods presented. On July 13, 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) 2017-11. Among other things, ASU 2017-11 provides guidance that eliminates the requirement to consider “down round” features when determining whether certain financial instruments or embedded features are indexed to an entity’s stock and need to be classified as liabilities. ASU 2017-11 provides for entities to recognize the effect of a down round feature only when it is triggered and then as a dividend and a reduction to income available to common stockholders in basic earnings per share. The guidance is effective for annual periods beginning after December 15, 2018. Accordingly, effective January 1, 2019, the Company reduced the derivative liability of warrants with “down round” features (and do not contain variable conversion features) of $108,427 at December 31, 2018 to $0 and recognized a $108,427 cumulative effect adjustment reduction of accumulated deficit.

Loans Payable to Related Part_2

Loans Payable to Related Parties (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Loans Payable to Related Parties	Loans payable to related parties consist of: December 31, 2020 December 31, 2019 Loans from Elisha Kalfa and Yonah Kalfa, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock $ 180,000 $ 180,000 Loan from Fernando Bisker and Sigalush, LLC, holders of a total of 2,966,666 shares of Series A Convertible Preferred stock 80,000 80,000 Total $ 260,000 $ 260,000

Notes Payable to Third Parties

Notes Payable to Third Parties (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Notes Payable to Third Parties	Notes payable to third parties consist of: December 31, 2020 December 31, 2019 Allonge to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 2,420 Allonge 2 to the Convertible Promissory Note dated September 14, 2017 payable to Emet Capital Partners, LLC (“EMET”), interest at 5%, due September 14, 2018 - 1,100 Promissory Note dated March 28, 2017 payable to John T. Root, Jr., interest at 4%, due September 28, 2017, convertible into shares of common stock at a conversion price of $.001 per share. 375 375 Convertible Convertible Note dated February 12, 2019 payable to Eagle Equities, LLC (“Eagle”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $33,396, respectively (i) 22,500 250,082 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $294,234, respectively (ii) - 74,566 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $90,054, respectively (ii) - 22,823 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $79,248, respectively (ii) - 20,084 Convertible Warrant Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 2%, due October 18, 2020-less unamortized debt discount of $0 and $9,005, respectively (ii) - 2,281 Convertible Promissory Note dated October 18, 2019 payable to Emet Capital Partners, LLC (“EMET”), interest at 6%, due February 12, 2020-less unamortized debt discount of $0 and $0, respectively (ii) - 25,587 Total $ 22,875 $ 399,318 (i) On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle was to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company’s common stock for the preceding 15 trading days prior to the conversion date. Please see Note G-DERIVATIVE LIABILITY for further information. (ii) On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note H) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date.

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liability	The derivative liability consists of: December 31, 2020 December 31, 2019 Convertible Promissory Note dated February 12, 2019 payable to Eagle Equities, LLC. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (i): Due February 12, 2020 $ 17,441 $ 182,625 Convertible Promissory Notes dated October 18, 2019 payable to Emet. Please see NOTE F – NOTES PAYABLE TO THIRD PARTIES for further information (ii): $451,505 note due October 18, 2021 - 328,953 $112,876 note due October 18, 2021 - 100,680 $ 99,331 note due October 18, 2021 - 88,599 $ 11,288 note due October 18, 2021 - 10,068 $ 25,587 note due October 18, 2021 - 14,940 Total derivative liability $ 17,441 $ 725,865

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Schedule of FF Note	The FF Note will mature on March 11, 2022. The FF Note may be pre-paid in whole or in part by paying FF the following premiums: PREPAY DATE PREPAY AMOUNT ≤ 30 days 105% * (Principal + Interest (“P+I”) 31- 60 days 110% * (P+I) 61-90 days 115% * (P+I) 91-120 days 120% * (P+I) 121-150 days 125% * (P+I) 151-180 days 130% * (P+I)

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jan. 04, 2019	Jul. 31, 2018	Mar. 10, 2017	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Number of shares issued	695,129		26,905,969
Advertising costs
Derivative liability				$ 17,441	$ 725,865	$ 0	$ 108,427
Cumulative effect of accumulated deficit						$ 108,427
Series A Convertible Preferred Stock [Member]
Anti-dilutive shares excluded from computation				470,599,900
Green C Corporation [Member] | Former Share Holders [Member]
Percentage of issued and outstanding shares acquired		94.00%
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued		9,411,998
Conversion of convertible preferred stock		50
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Green C Corporation [Member] | Class A Common Stock [Member]
Percentage of issued and outstanding shares acquired		100.00%
Common stock, voting rights		Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 112,953				$ 24,662				$ 112,953	$ 24,662
Current liabilities	459,908								459,908
Working capital deficit	(300,205)								(300,205)
Net loss	$ (382,790)	$ (459,260)	$ 1,102,449	$ (1,211,569)	$ (1,096,037)	$ (126,430)	$ (287,779)	$ (138,349)	(951,170)	(1,648,595)
Net cash provided in operating activities									$ (289,627)	$ (285,229)

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	Dec. 31, 2020	Jun. 10, 2020	Dec. 31, 2019
Notes receivable	$ 36,750
Kol Tuv Ventures, LLC [Member]
Interest rate		2.00%

Loans Payable to Related Part_3

Loans Payable to Related Parties (Details Narrative)	Jul. 31, 2018USD ($)
Loan and Contribution Agreements [Member] | Maximum [Member]
Repayment of related party debt	$ 1,500,000

Loans Payable to Related Part_4

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 260,000	$ 260,000
Elisha Kalfa and Yonah Kalfa [Member]
Total	180,000	180,000
Fernando Bisker and Sigalush, LLC [Member]
Total	$ 80,000	$ 80,000

Loans Payable to Related Part_5

Loans Payable to Related Parties - Schedule of Loans Payable to Related Parties (Details) (Parenthetical) - Series A Convertible Preferred Stock [Member] - shares	Dec. 31, 2020	Dec. 31, 2019
Number of shares held by holders of preferred stock	9,411,998	9,411,998
Elisha Kalfa and Yonah Kalfa [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666
Fernando Bisker and Sigalush, LLC [Member]
Number of shares held by holders of preferred stock	2,966,666	2,966,666

Notes Payable to Third Partie_2

Notes Payable to Third Parties (Details Narrative) - USD ($)	May 26, 2020	Jun. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 24, 2019	Dec. 20, 2019	Nov. 11, 2019	Oct. 18, 2019	Apr. 16, 2019	Jan. 04, 2019
Payments for notes payable		$ 542,170
Notes payable		67,082	$ 325,212	$ 311,050	$ 165,350	$ 10,000	$ 29,000	$ 53,705		$ 40,500	$ 670
Notes payable excess amount		472,170
Gain on satisfaction of debt		$ 70,000
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member]
Payments for notes payable	$ 70,000
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable One [Member]
Notes payable									$ 3,129
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable Two [Member]
Notes payable									15,440
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Redeemable [Member]
Notes payable									7,018
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note [Member]
Notes payable									451,505
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note One [Member]
Notes payable									112,876
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note Two [Member]
Notes payable									99,331
Surrender Agreement [Member] | Emet Capital Partners, LLC [Member] | Convertible Note Three [Member]
Notes payable									$ 11,288

Notes Payable to Third Partie_3

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) - USD ($)		Dec. 31, 2020	Dec. 31, 2019
Notes payable to third parties, total		$ 22,875	$ 399,318
Convertible Promissory Note One [Member]
Notes payable to third parties, total			2,420
Convertible Promissory Note Two [Member]
Notes payable to third parties, total			1,100
Promissory Note [Member]
Notes payable to third parties, total		375	375
Convertible Convertible Note One [Member]
Notes payable to third parties, total	[1]	22,500	250,082
Convertible Warrant Note One [Member]
Notes payable to third parties, total	[2]		74,566
Convertible Warrant Notes Two [Member]
Notes payable to third parties, total	[2]		22,823
Convertible Warrant Notes Three [Member]
Notes payable to third parties, total	[2]		20,084
Convertible Warrant Notes Four [Member]
Notes payable to third parties, total	[2]		2,281
Convertible Promissory Note Three [Member]
Notes payable to third parties, total	[2]		$ 25,587
[1]	On February 12, 2019, (the “Issue Date”) the Company issued a 6% Convertible Redeemable Note to Eagle Equities, LLC (“Eagle”), having a principal amount of $1,200,000 of which $96,000 constituted an original issue discount (the “Eagle Note”). In connection with the Eagle Note, the Company and Eagle entered into a Securities Purchase Agreement. Eagle was to fund the $ 1,104,000 purchase price of the Eagle Note in tranches. The first tranche of $ 250,000 was received by the Company on February 13, 2019. The second tranche of $ 166,500 was received by the Company on January 17, 2020, the third tranche of $ 93,666 was received by the Company on February 12, 2020, and the fourth tranche of $ 42,500 was received by the Company on June 3, 2020. The loans are repayable one year from their respective funding dates and are convertible at the option of Eagle at a conversion price equal to 65% of the lowest closing price of the Company’s common stock for the preceding 15 trading days prior to the conversion date. Please see Note G-DERIVATIVE LIABILITY for further information.
[2]	On October 18, 2019, the Company entered into two Exchange Agreements with Emet Capital Partners, LLC (“Emet”). The first Exchange Agreement provided for the exchange of three outstanding convertible notes payable to Emet with a total remaining principal balance of $20,399 and a total accrued interest balance of $5,189 for three new convertible notes payable to Emet in the total amount of $25,587. The new notes bore interest at 6%, were due on February 12, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date. The second Exchange Agreement provided for the reversal of the February 14, 2019 exchange agreement pursuant to which certain warrants then held by Emet were exchanged for 9,000,000 shares of Series B Convertible Preferred Stock (see Note H) and the exchange of such warrants for four new convertible notes payable to Emet in the total amount of $675,000. These new notes bore interest at 2%, were due on October 18, 2020 and were convertible into common stock at a conversion price equal to 75% of the lowest Trading Price during the 15 Trading Day Period prior to the Conversion Date.

Notes Payable to Third Partie_4

Notes Payable to Third Parties - Schedule of Notes Payable to Third Parties (Details) (Parenthetical)	Jun. 03, 2020USD ($)	Feb. 12, 2020USD ($)	Jan. 17, 2020USD ($)	Dec. 24, 2019USD ($)shares	Dec. 20, 2019USD ($)shares	Nov. 11, 2019USD ($)shares	Oct. 18, 2019USD ($)Integer	Apr. 16, 2019USD ($)shares	Feb. 14, 2019shares	Feb. 13, 2019USD ($)	Feb. 12, 2019USD ($)	Jan. 04, 2019USD ($)shares	Sep. 14, 2017	Mar. 28, 2017$ / shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)Integer	Dec. 31, 2019USD ($)
Debt instrument, principal amount															$ 325,212	$ 311,050	$ 67,082	$ 165,350	$ 325,212
Accrued interest				$ 515	$ 4,035	$ 2,680		$ 7,961				$ 100			$ 16,849	$ 18,462	$ 10,613	$ 11,793	16,849
Debt conversion converted shares issued | shares				637,273	1,468,204	1,748,363		1,384,600				769,785			261,215,948	115,277,834	27,563,525	21,484,688
Allonge [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate													5.00%
Debt instrument, maturity date													Sep. 14, 2018
Allonge 2 [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate													5.00%
Debt instrument, maturity date													Sep. 14, 2018
Promissory Note [Member] | John T. Root [Member]
Debt instrument, interest rate														4.00%
Debt instrument, maturity date														Sep. 28, 2017
Conversion price | $ / shares														$ 0.001
Convertible Convertible Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate											6.00%
Debt instrument, principal amount											$ 1,200,000
Convertible Convertible Note One [Member] | Eagle Equities, LLC [Member]
Unamortized debt discount															$ 0				$ 0	$ 33,396
Trading days percentage																			65.00%
Trading days period | Integer																			15
Debt instrument, term																			1 year
Convertible Promissory Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate							6.00%
Debt instrument, maturity date							Oct. 18, 2021
Unamortized debt discount															0				$ 0	0
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date											Feb. 12, 2020
Debt conversion, original issue discount											$ 96,000
Funding value of issuance of note											$ 1,104,000
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | First Tranche [Member]
Proceeds from issuance of convertible debt										$ 250,000
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Second Tranche [Member]
Proceeds from issuance of convertible debt			$ 166,500
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Third Tranche [Member]
Proceeds from issuance of convertible debt		$ 93,666
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member] | Four Tranche [Member]
Proceeds from issuance of convertible debt	$ 42,500
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate							2.00%
Debt instrument, maturity date							Oct. 18, 2020
Unamortized debt discount															0				0	294,234
Debt conversion converted shares issued | shares									9,000,000
Convertible Warrant Note One [Member] | Emet Capital Partners, LLC [Member] | First Exchange Agreement [Member]
Debt instrument, interest rate							6.00%
Debt instrument, maturity date							Feb. 12, 2020
Debt instrument, principal amount							$ 20,399
Trading days percentage							75.00%
Trading days period | Integer							15
Accrued interest							$ 5,189
Debt instrument, periodic payment							$ 25,587
Four New Convertible Warrant Notes [Member] | Emet Capital Partners, LLC [Member] | Second Exchange Agreement [Member]
Debt instrument, interest rate							2.00%
Debt instrument, maturity date							Oct. 18, 2020
Trading days percentage							75.00%
Trading days period | Integer							15
Debt instrument, periodic payment							$ 675,000
Convertible Warrant Notes Two [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate							2.00%
Debt instrument, maturity date							Oct. 18, 2020
Unamortized debt discount															0				0	90,054
Convertible Warrant Notes Three [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate							2.00%
Debt instrument, maturity date							Oct. 18, 2020
Unamortized debt discount															0				0	79,248
Convertible Warrant Notes Four [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, interest rate							2.00%
Debt instrument, maturity date							Oct. 18, 2020
Unamortized debt discount															$ 0				$ 0	$ 9,005

Derivative Liability (Details N

Derivative Liability (Details Narrative) - Convertible Promissory Notes [Member]	12 Months Ended
	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Fair value of assumption stock price	$ 0.003	$ 0.0330
Measurement Input, Exercise Price [Member]
Derivative liability measurement input	0.00169
Measurement Input, Exercise Price [Member] | Minimum [Member]
Derivative liability measurement input		0.01885
Measurement Input, Exercise Price [Member] | Maximum [Member]
Derivative liability measurement input		0.02175
Measurement Input, Expected Term [Member]
Fair value of assumption term	0 days
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value of assumption term		293 days
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value of assumption term		43 days
Measurement Input, Price Volatility [Member]
Derivative liability measurement input	142.94	142.94
Measurement Input, Risk Free Interest Rate [Member]
Derivative liability measurement input	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liability measurement input		1.50
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liability measurement input		1.60

Derivative Liability - Schedule

Derivative Liability - Schedule of Derivative Liability (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Total derivative liability	$ 17,441	$ 725,865	$ 0	$ 108,427
Convertible Promissory Notes One [Member]
Total derivative liability	17,441	182,625
Convertible Promissory Notes Two [Member]
Total derivative liability		328,953
Convertible Promissory Notes Three [Member]
Total derivative liability		100,680
Convertible Promissory Notes Four [Member]
Total derivative liability		88,599
Convertible Promissory Notes Five [Member]
Total derivative liability		10,068
Convertible Promissory Notes Six [Member]
Total derivative liability		$ 14,940

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Derivative Liability (Details) (Parenthetical) - USD ($)	Oct. 18, 2019	Feb. 12, 2019
Convertible Promissory Note One [Member] | Eagle Equities, LLC [Member]
Debt instrument, maturity date		Feb. 12, 2020
Convertible Promissory Note One [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date	Oct. 18, 2021
Notes payable to related parties	$ 451,505
Convertible Promissory Note Two [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date	Oct. 18, 2021
Notes payable to related parties	$ 112,876
Convertible Promissory Note Three [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date	Oct. 18, 2021
Notes payable to related parties	$ 99,331
Convertible Promissory Note Four [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date	Oct. 18, 2021
Notes payable to related parties	$ 11,288
Convertible Promissory Note Five [Member] | Emet Capital Partners, LLC [Member]
Debt instrument, maturity date	Oct. 18, 2021
Notes payable to related parties	$ 25,587

Capital Stock and Warrants (Det

Capital Stock and Warrants (Details Narrative)	Dec. 24, 2019USD ($)shares	Dec. 20, 2019USD ($)shares	Nov. 11, 2019USD ($)shares	Oct. 18, 2019USD ($)Integer	Aug. 15, 2019USD ($)shares	May 29, 2019shares	Apr. 16, 2019USD ($)shares	Feb. 14, 2019$ / sharesshares	Jan. 04, 2019USD ($)$ / sharesshares	Jan. 04, 2019USD ($)$ / sharesshares	Jul. 31, 2018shares	Mar. 10, 2017shares	Feb. 03, 2017shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2020USD ($)shares	Jun. 30, 2020USD ($)shares	Mar. 31, 2020USD ($)shares	Jun. 30, 2019USD ($)shares	Mar. 31, 2019USD ($)shares	May 25, 2017shares
Number of shares issued during the period, shares									695,129			26,905,969
Debt conversion converted shares issued	637,273	1,468,204	1,748,363				1,384,600		769,785					261,215,948	115,277,834	27,563,525	21,484,688
Debt instrument, principal amount | $														$ 325,212	$ 311,050	$ 67,082	$ 165,350
Accrued interest | $	$ 515	$ 4,035	$ 2,680				$ 7,961		$ 100	$ 100				16,849	18,462	10,613	11,793
Number of shares issued for services																		542,000
Value of shares issued for services | $																		$ 75,880
Conversion of note payable, principal amount | $	10,000	29,000	53,705				40,500		670	$ 670				325,212	311,050	67,082	165,350
Number of stock value issued for debt conversion | $	$ 25,491	$ 58,728	$ 104,901				$ 179,998		$ 100,072					804,324	797,067	210,532	406,093
Excess of fair value | $														462,263	467,554	132,838	228,949
Liability reduction | $														$ 342,061	$ 329,512	$ 77,695	$ 177,143
Warrants to purchase common stock									1,400	1,400
Two Consulting Firm Entities [Member]
Number of shares issued for services						542,000
Investor Relations And Advisory Services [Member] | Common Stock [Member]
Number of shares issued for services																		542,000
Emet Capital Partners, LLC [Member] | Convertible Warrant Note One [Member]
Debt conversion converted shares issued								9,000,000
Debt instrument, interest rate				2.00%
Debt instrument, maturity date				Oct. 18, 2020
Emet Capital Partners, LLC [Member] | Convertible Warrant Note One [Member] | First Exchange Agreement [Member]
Debt instrument, principal amount | $				$ 20,399
Accrued interest | $				5,189
Debt instrument, periodic payment | $				$ 25,587
Debt instrument, interest rate				6.00%
Debt instrument, maturity date				Feb. 12, 2020
Trading days percentage				75.00%
Trading days period | Integer				15
Emet Capital Partners, LLC [Member] | Four New Convertible Warrant Notes [Member] | Second Exchange Agreement [Member]
Debt instrument, periodic payment | $				$ 675,000
Debt instrument, interest rate				2.00%
Debt instrument, maturity date				Oct. 18, 2020
Trading days percentage				75.00%
Trading days period | Integer				15
Emet Capital Partners, LLC [Member] | Four New Convertible Warrant Notes [Member] | Exchange Agreement [Member]
Debt instrument, periodic payment | $				$ 675,000
Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares							1,384,600			695,129
Conversion price | $ / shares									$ 0.001	$ 0.001
Debt conversion converted shares issued										769,785									769,785
Debt instrument, principal amount | $							$ 40,500		$ 670	$ 670
Accrued interest | $							$ 7,961		$ 100	$ 100
Excess of common stock value | $																		$ 131,537	$ 99,302
Fair value of common stock | $					$ 12,250													179,998	100,072
Loss on conversion of debt | $																		$ 47,961	$ 770
Number of warrant issued									1,400	1,400										440,000
Warrant exercise price | $ / shares								$ 0.075	$ 0.001	$ 0.001
Excess of common stock, shares																		1,384,600
Number of shares issued for services					175,000
Warrants to purchase common stock								9,000,000
Number of warrant outstanding
Sylios Corp [Member]
Ownership percentage												19.99%	80.01%
Number of shares issued during the period, shares												5,378,476	21,527,493
Common stock, shares held													500
Series A Convertible Preferred Stock [Member] | Green C Corporation [Member]
Number of shares issued during the period, shares											9,411,998
Number of common stock converted											50
Common stock, voting rights											Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.
Series B Convertible Preferred Stock [Member] | Emet Capital Partners, LLC [Member]
Number of shares issued during the period, shares								9,000,000
Conversion price | $ / shares								$ 0.075
Preferred stock conversion basis, description								Each share of Series B Convertible Preferred Stock was convertible into one share of Company common stock subject to adjustment in case, at the time of conversion, the market price per share of the Company common stock was less than $ 0.075 per share.
Green C Corporation [Member] | Class A Common Stock [Member]
Ownership percentage											100.00%
Common stock, voting rights											Each share of Series A Convertible Preferred Stock is convertible into 50 shares of common stock and is entitled to vote 50 votes per share on all matters as a class with holders of common stock.

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	May 27, 2020	Jul. 15, 2019	Jul. 31, 2018	Jun. 26, 2018	Jun. 21, 2018	Dec. 31, 2020	Dec. 31, 2019
Minimum annual royalty amount							$ 50,000
Forgiveness of royalty payable						50,000
Officers compensation						204,000	204,000
Pharmedica, Ltd. [Member]
Minimum annual royalty amount						50,000
Impairment charge						69,749
Reduction of carrying value of assets							69,749
Intangible assets							0
Exclusive License Agreement [Member] | Green C's Corporation [Member]
License fee					$ 100,000
Annual royalties rate				5.00%
Minimum annual royalty amount				$ 50,000
Forgiveness of royalty payable						50,000
Reduction of accrued royalties						50,000
Accrued royalties						0
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Minimum [Member]
Annual royalties rate		10.00%
Sub-License Agreement [Member] | Symtomax Unipessoal Lda [Member] | Maximum [Member]
Annual royalties rate		17.00%
Royalty payment	$ 1,000,000
Services Agreements [Member] | Chief Executive Officer [Member]
Officers compensation			$ 10,000
Services Agreements [Member] | Chief Legal Officer [Member]
Officers compensation			$ 7,000
Services Agreements [Member]
Officers compensation						$ 204,000	$ 204,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 15, 2021	Jan. 06, 2021	Jan. 04, 2019	Mar. 10, 2017	Mar. 11, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Number of shares issued			695,129	26,905,969
Debt instrument principal amount						$ 325,212	$ 311,050	$ 67,082	$ 165,350
Warrants to purchase shares of common stock			1,400
Subsequent Event [Member]
Number of shares issued		13,795,118
Debt instrument principal amount		$ 22,500
Debt instrument interest amount		$ 814
Subsequent Event [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Warrant A [Member]
Warrants to purchase shares of common stock					25,000,000
Warrants exercise price per share					$ 0.025
Subsequent Event [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Warrant B [Member]
Warrants to purchase shares of common stock					15,000,000
Warrants exercise price per share					$ 0.05
Subsequent Event [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Warrant C [Member]
Warrants to purchase shares of common stock					10,000,000
Warrants exercise price per share					$ 0.075
Subsequent Event [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Warrant [Member]
Warrants exercise price per share					$ 0.005
Subsequent Event [Member] | Convertible Promissory Note [Member] | FirstFire Global Opportunities Fund, LLC [Member]
Debt instrument principal amount	$ 545,000
Debt instrument interest rate percentage	6.00%
Original issue discount	$ 545,000
Proceeds from convertible promissory note	272,500
Subsequent Event [Member] | Convertible Promissory Note [Member] | FirstFire Global Opportunities Fund, LLC [Member] | Initial Tranche [Member]
Debt instrument principal amount	$ 272,500
Subsequent Event [Member] | FF Note [Member] | FirstFire Global Opportunities Fund, LLC [Member]
Debt instrument interest rate percentage	24.00%
Debt instrument maturity date	Mar. 11, 2022
Conversion price percentage	70.00%
Debt repayment percentage	125.00%

Subsequent Events - Schedule of

Subsequent Events - Schedule of FF Note (Details) - FF Note [Member] - Subsequent Event [Member]	Mar. 15, 2021
≤ 30 days [Member]
Pre-payment of convertible promissory note percentage	105% * (Principal + Interest ("P+I")
31 - 60 Days [Member]
Pre-payment of convertible promissory note percentage	110% * (P+I)
61 - 90 Days [Member]
Pre-payment of convertible promissory note percentage	115% * (P+I)
91 - 120 Days [Member]
Pre-payment of convertible promissory note percentage	120% * (P+I)
121 - 150 Days [Member]
Pre-payment of convertible promissory note percentage	125% * (P+I)
151 - 180 Days [Member]
Pre-payment of convertible promissory note percentage	130% * (P+I)